- Home
- SKYE vs SEGG Comparison
SKYE vs SEGG Comparison
Compare SKYE & SEGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | SEGG |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 19.9M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SKYE | SEGG |
|---|---|---|
| Price | $0.72 | $2.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $15.00 | ★ $20.00 |
| AVG Volume (30 Days) | 190.3K | ★ 4.8M |
| Earning Date | 05-08-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.46 |
| 52 Week High | $5.75 | $7.61 |
Technical Indicators
Market Signals| Indicator | SKYE | SEGG |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 72.74 |
| Support Level | $0.71 | $0.74 |
| Resistance Level | $0.83 | $4.90 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 5.55 | 76.55 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is a sports, entertainment and gaming group operating digital assets such as Sports.com and Lottery.com. It is focused on immersive fan engagement, ethical gaming and AI-driven live experiences.